Attached files

file filename
EX-99.1 - OBAGI MEDICAL PRODUCTS EARNINGS RELEASE - Obagi Medical Products, Inc.earningsrelease.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):   May 3, 2012
 
Obagi Medical Products, Inc.
(Exact name of registrant as specified in its charter)
  
001-33204
(Commission File Number)
  
Delaware
 
22-3904668
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification No.)
 
3760 Kilroy Airport Way, Suite 500, Long Beach, CA 90806
 (Address of principal executive offices, with zip code)
  
(562) 628-1007
(Registrant’s telephone number, including area code)
  
 (Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see   General Instruction A.2. below): 
 
 
o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    


 
 

 

Item 2.02 Results of Operation and Financial Condition

On May 3, 2012, Obagi Medical Products, Inc. issued a press release announcing financial results for the three months ended March 31, 2012.  A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated herein by reference.

The information furnished herewith pursuant to Item 2.02 of this Current Report and in Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 2.02 and in Exhibit 99.1 hereto shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, regardless of any general incorporation language contained in such filing, except as shall be expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

 (d)           Exhibits
   
Exhibit Number
 
Description
99.1
 
Press Release of Obagi Medical Products, Inc. dated May 3, 2012

 
 

 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
OBAGI MEDICAL PRODUCTS, INC.
 
       
Date:  May 3, 2012
By:
/s/ Preston S. Romm
 
   
Preston S. Romm
 
   
Chief Financial Officer